Merck has completed its acquisition of the chromatography business of JSR Life Sciences, adding Amsphere Protein A resins and related purification capabilities to its bioprocessing portfolio. The move bolsters Merck’s downstream offering for monoclonal antibody manufacturing, an area where efficient Protein A capture remains central to productivity and scale-up.
The acquired business brings more than 50 employees based in Belgium, along with technical and application expertise in chromatography for pharmaceutical and biotech manufacturers. Merck says these capabilities will be integrated into its Process Solutions business, supporting customers from process development through commercial production.
“This acquisition expands our downstream purification capabilities at a time when customers are pushing to scale biologics faster and more efficiently,” said Sebastián Arana, Head of Process Solutions in Merck’s Life Science business. He added that the expanded Protein A portfolio should help improve process consistency, support reliable manufacturing at scale, and accelerate access to critical therapies.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
